Abstract
Background As of April 2021, three SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351 and P.1) have been detected in over 132 countries. Increased transmissibility of VOC has implications for public health measures and health system arrangements. This rapid scoping review aims to provide a synthesis of current evidence related to public health measures and health system arrangements associated with VOC.
Methods Rapid scoping review. Seven databases were searched up to April 7, 2021 for terms related to VOC, transmission, public health and health systems. A grey literature search was conducted up to April 14, 2021. Title, abstracts and full text were screened independently by two reviewers. Data were double extracted using a standardized form. Studies were included if they reported on at least one of the VOC and public health or health system outcomes.
Results Of the 2487 articles and 59 grey literature sources retrieved, 37 studies and 21 guidance documents were included. Included studies used a wide range of designs and methods. Most of the studies and guidance documents reported on B.1.1.7, and 18 studies and 4 reports provided data for consideration in relation to public health measures. Public health measures, including lockdowns, physical distancing, testing and contact tracing, were identified as critical adjuncts to a comprehensive vaccination campaign. No studies reported on handwashing or masking procedures related to VOC. For health system arrangements, 17 studies were identified. Some studies found an increase in hospitalization due to B.1.1.7 but no difference in length of stay or ICU admission. Six studies found an increased risk of death ranging from 15-67% with B.1.1.7 compared non-B.1.1.7, but three studies reported no change. One study reported on the effectiveness of personal protective equipment in reducing VOC transmission in the hospital. No studies reported on screening staff and visitors, adjusting service provisions, or adjusting patient accommodations and shared spaces, which is a significant gap in the literature. Guidance documents did not tend to cite any evidence and were thus assumed to be based on expert opinion.
Conclusion While the findings should be interpreted with caution as most of the sources identified were preprints, findings suggest a combination of non-pharmaceutical interventions (e.g., masking, physical distancing, lockdowns, testing) should be employed alongside a vaccine strategy to improve population and health system outcomes. While the findings are mixed on the impact of VOC on health system arrangements, the evidence is trending towards increased hospitalization and death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is support by: The SPOR Evidence Alliance (SPOR EA), which is supported by the Canadian Institutes of Health Research (CIHR) under the Strategy for Patient-Oriented Research (SPOR) initiative, and the COVID-19 Evidence Network to support Decision-making (COVID-END), which is supported by the Canadian Institutes of Health Research (CIHR) through the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding opportunity.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethical approval was required as it is a review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon reasonable request from corresponding author.
Definitions & Abbreviations
- ABM
- Agent-based Model
- AGREE II
- Appraisal of Guidelines Research and Evaluation
- aIRR
- adjusted incidence rate ratios
- B.1.1.7
- variant of concern originating in the United Kingdom, also known as VUI 202012/01 and VOC 202012/01
- B.1.351
- variant of concern originating in South Africa, also known as 20H/501Y.V2
- BMI
- body mass index
- CanCOGen
- Canadian COVID Genomics Network
- CENTRAL
- Central Register of Controlled Trials
- CFR
- Case Fatality Rates
- CI
- confidence interval
- CIDRAP
- Center for Infectious Disease Research and Policy
- Ct
- cycle threshold, provides a relative measure of viral quantity
- COG-UK
- COVID-19 Genomics UK
- CDSR
- Cochrane Database of Systematic Reviews
- dQALY
- discounted quality-adjusted life years
- E484K
- escape mutation in the SARS-CoV-2 virus, present in B.1.1.7
- ECDC
- European Centres for Disease Control
- FDA
- Food and Drug Administration
- HCW
- healthcare workers
- HR
- Hazard Ratio
- HVAC
- heating, ventilation, and air conditioning
- ICU
- Intensive Care Unit
- IQR
- interquartile range
- IR
- incidence rate
- LOS
- length of stay
- mRNA
- messenger ribonucleic acid
- NGS
- next generation sequencing
- NOS
- Newcastle-Ottawa scale
- NPI
- Non-Pharmaceutical Interventions
- NRW
- North-Rhine Westphalia
- OR
- odds ratio
- P.1
- variant of concern originating in Brazil, also known as B.1.28.1
- PCR
- polymerase chain reaction, method for DNA replication and genome sequencing
- PHU
- Public Health Unit
- PPE
- personal protective equipment
- PR
- prevalence ratio
- R
- reproduction
- R0
- basic reproduction number, expected number of cases generated by one case in a population when everyone is susceptible to infection
- Rt
- effective reproduction number
- RR
- risk ratio
- RT-LAMP
- reverse transcription loop-mediated and transcription-mediated amplification isothermal amplification
- RTD
- Rapid Antigen Test
- SA
- South Africa
- SAPSII
- severity score at admission
- SIDARTHE
- a type of model
- SGTF
- spike OR S gene target failure, correlates with the increase of confirmed, sequenced variants
- SGTL
- spike gene late detection
- SD
- standard deviation
- UK
- United Kingdom
- US
- United States
- VE
- vaccine efficiency
- VOC
- variant of concern
- WHO
- World Health Organization
- WGS
- whole genome sequencing